Literature DB >> 17760666

Changes in the tumor grade and biological markers in locally advanced breast cancer after chemotherapy--implications for a pathologist.

Tanuja Shet1, Atin Agrawal, Roshni Chinoy, Rohini Havaldar, Vani Parmar, Rajan Badwe.   

Abstract

There is insurgence of literature evaluating prognostic and predictive factors in breast carcinomas treated with chemotherapy, with a parallel need to develop guidelines for the pathologist interpreting such excisions. Prechemotherapy gun biopsy and postchemotherapy excision specimens from 78 women with locally advanced breast cancer were analyzed for histological changes in the tumor, changes in the tumor grade, hormone receptors, cerb2, and bcl2 and their impact on disease-free survival (DFS). An unusually prominent granulomatous response to tumor was seen in three cases. The tumor grade changed in five patients, estrogen receptor (ER) expression was altered in 10 cases, progesterone receptor detection changed in 16 cases, cerb2 in one case and bcl2 in 16 cases. Fixation of the gun biopsy in Bouin's fluid and severe damage of nuclei after chemotherapy were the reasons for shift in the expression of hormone receptors. A low-grade tumor was associated with better response to chemotherapy. In the Kaplan-Meier analysis the ER expression and a low-grade tumor (grade I and II) significantly affected DFS. None of the factors evaluated impacted the overall survival of patients. To conclude there is a change in the tumor grade, bcl2, cerb2 and hormone receptors after chemotherapy. A pathologist interpreting specimens of breast cancer after chemotherapy must always record the postchemotherapy grade as it is an indicator of better response to chemotherapy and survival.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17760666     DOI: 10.1111/j.1524-4741.2007.00465.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  10 in total

1.  Prognostic value of hormone receptor status conversion following neoadjuvant chemotherapy in a series of operable breast cancer patients.

Authors:  Qi-Xing Tan; Qing-Hong Qin; Wei-Ping Yang; Bin Lian; Chang-Yuan Wei
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

2.  Evaluation of biomarker changes after administration of various neoadjuvant chemotherapies in breast cancer.

Authors:  Guangchao Jin; Yu Han; Cun Liu; Liansheng Chen; Butong Ding; Shijin Xuan; Xianqiang Liu; Guohui Ma; Jun Gao; Xingsong Tian
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

3.  Discordance of Estrogen & Progesterone Receptors After Neoadjuvant Chemotherapy in Breast Cancer- an Indian Study.

Authors:  Aravindh Sivanandan Anand; Sandeep Thekoot Velayudhan
Journal:  Indian J Surg Oncol       Date:  2016-02-25

4.  Neoadjuvant treatment of breast cancer.

Authors:  A M Thompson; S L Moulder-Thompson
Journal:  Ann Oncol       Date:  2012-09       Impact factor: 32.976

5.  Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.

Authors:  Xi Jin; Yi-Zhou Jiang; Sheng Chen; Ke-Da Yu; Zhi-Ming Shao; Gen-Hong Di
Journal:  Oncotarget       Date:  2015-04-20

6.  Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?

Authors:  Yu Ishimine; Akira Goto; Yoshito Watanabe; Hidetaka Yajima; Suguru Nakagaki; Takashi Yabana; Takeya Adachi; Yoshihiro Kondo; Kiyoshi Kasai
Journal:  Case Rep Gastrointest Med       Date:  2015-03-29

7.  Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy.

Authors:  Libo Yang; Xiaorong Zhong; Tianjie Pu; Yan Qiu; Feng Ye; Hong Bu
Journal:  World J Surg Oncol       Date:  2018-03-07       Impact factor: 2.754

8.  Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer.

Authors:  Ling-Cheng Wang; Ling-Sheng Wang; Ai-Xia Li; Zhen-Zong Shi; Ya-Qiong Li; Wei Huang; Shi-Man Chen; Fei Han; De-Qiang Zhu
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

9.  Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer.

Authors:  T Hirata; C Shimizu; K Yonemori; A Hirakawa; T Kouno; K Tamura; M Ando; N Katsumata; Y Fujiwara
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

Review 10.  Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis.

Authors:  Miaomiao Tao; Shu Chen; Xianquan Zhang; Qi Zhou
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.